Funded in part by Danone
The chronic kidney disease Water Intake Trial (WIT): results from the pilot randomised controlled trial
Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, Weir MA, Garg AX
BMJ open · 31 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Danone
Based on 1 listed funder(s).
Publication
- Published
- 2013-12-01 · BMJ Open · vol. 3 · issue 12 · p. e003666
- Publisher
- BMJ
- Cited
- 38 citations · more than 92% of similar papers · 3.3× the field average
- Impact
- Top 10% most cited in its field
- References
- 31 works
- Access
- Open access (journal) · CC-BY-NC
- Research areas
- Sodium Intake and Health · Chronic Kidney Disease and Diabetes · Dialysis and Renal Disease Management
- Keywords
- Medicine, Renal function, Urine, Albuminuria, Kidney disease, Randomized controlled trial, Creatinine, Internal medicine, Urology
8 authors
From CA
- William F. Clark · correspondingLondon Health Sciences Centre
- Jessica M. SontropWestern University; London Health Sciences Centre
- Shih‐Han Susan HuangLondon Health Sciences Centre
- Kerri GalloWestern University
- Louise M. MOISTWestern University; London Health Sciences Centre
- Andrew A. HouseLondon Health Sciences Centre
Abstract
Background and objectives
Increased water intake may benefit kidney function. Prior to initiating a larger randomised controlled trial (RCT), we examined the safety and feasibility of asking adults with chronic kidney disease (CKD) to increase their water intake.
Design, setting, participants and measurements
Beginning in October 2012, we randomly assigned 29 adults with stage 3 CKD (estimated glomerular filtration rate (eGFR) 30-60 mL/min/1.73 m(2) and albuminuria) to one of the two groups of water intake: hydration (n=18) or standard (n=11). We asked the hydration group to increase their water intake by 1.0-1.5 L/day (in addition to usual intake, depending on sex and weight) for 6 weeks, while the control group carried on with their usual intake. Participants collected a 24 h urine sample at baseline and at 2 and 6 weeks after randomisation. Our primary outcome was the between-group difference in change in 24 h urine volume from baseline to 6 weeks.
Results
(63%)of participants were men, 81% were Caucasians and the average age was 61 years (SD 14 years). The average baseline eGFR was 40 mL/min/1.73 m(2) (SD 11 mL/min/1.73 m(2)); the median albumin to creatinine ratio was 19 mg/mmol (IQR 6-74 mg/mmol). Between baseline and 6-week follow-up, the hydration group's average 24 h urine volume increased by 0.7 L/day (from 2.3 to 3.0 L/day) and the control group's 24 h urine decreased by 0.3 L/day (from 2.0 to 1.7 L/day; between-group difference in change: 0.9 L/day (95% CI 0.4 to 1.5; p=0.002)). We found no significant changes in urine, serum osmolality or electrolyte concentrations, or eGFR. No serious adverse events or changes in quality of life were reported.
Conclusions
A pilot RCT indicates adults with stage 3 CKD can successfully and safely increase water intake by up to 0.7 L/day in addition to usual fluid intake. TRIAL REGISTRATION REGISTERED WITH CLINICAL TRIALSGOVERNMENT IDENTIFIER: NCT01753466.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.